Sabah Oney

Sabah Oney is the president and CEO of Dispatch Bio, a Philadelphia- and San Francisco-based biotech engineering a universal treatment for solid tumors using CAR-T cell therapy. Born in Cyprus and in the U.S. since age 18, he holds a genetics degree from the University of Kansas, a PhD in genetics and genomics from Duke, and an MBA from Stanford. Across nearly two decades in biotech he helped scale Ariosa Diagnostics (acquired by Roche), took Alector public as its chief business officer, co-founded Vilya, and served as a venture partner at ARCH. Dispatch launched publicly in 2025 with $216 million behind its FLARE platform and CAR-T pioneer Carl June among its founders.